Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine

Scipher Medicine announced that Galapagos (NASDAQ:GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher's Spectra platform. In August 2020, Galapagos and Scipher Medicine agreed to jointly validate a suite of novel IBD targets discovered by Spectra. Galapagos has the exclusive option to in-license certain validated preclinical targets…

Genocea Closes Shop, Delists From NASDAQ

Genocea Closes Shop, Delists From NASDAQ

Genocea Biosciences Inc's (NASDAQ:GNCA) board has voted to wind down the company's ongoing operations and terminate the remaining employees except those deemed necessary to complete an orderly wind down. Yesterday, the company delivered formal notice to The Nasdaq Stock Market Inc of its intent to delist voluntarily and its plans to file a…

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults. NeoCart is a three-dimensional tissue-engineered disc of…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Snap's Warning Has Implications For These 6 Stocks

Snap set early alarm bells ringing for social media companies with its warning concerning second-quarter performance. An analyst at KeyBanc Capital Markets sees a read-across for these six companies.

Washington Attorney General Indicts Meta's Mark Zuckerberg For Alleged Role In Cambridge Analytica Scandal

The attorney general for Washington, D.C., charged Meta Platforms Inc (NASDAQ:FB) Facebook founder Mark Zuckerberg for allegedly participating in decision-making that led to the Cambridge Analytica data breach, the Wall Street Journal reports. The evidence shows Zuckerberg was personally involved in Facebook’s failure to protect the privacy and data of its users leading…

Why Elbit Systems Stock Is Sliding Today

Elbit Systems Ltd (NASDAQ:ESLT) reported first-quarter FY22 revenue growth of 21% year-over-year to $1.35 billion, with a significant part of the growth being organic, in addition to the contribution of Sparton. Adjusted gross margin declined 100 bps to 24.6%. Adjusted operating margin contracted to 4.9% from 8.3% in 1Q21. Adjusted EPS fell to…

Nvidia Announces New Liquid-Cooled GPUs: How It Will Double Data Center Computing Power

Nvidia Corporation (NASDAQ: NVDA) made a splash with its announcements at "Computex 2022," that is currently underway in Taiwan.

inkl

Read news from The Economist, FT, and more,
with one subscription

Activision Blizzard Employees Proceed Towards Unionization

Activision Blizzard Employees Proceed Towards Unionization

Twenty-two quality-assurance testers at Activision Blizzard, Inc (NASDAQ:ATVI) studios have voted in favor of unionizing with the Communications Workers of America, the Wall Street Journal reports. The workers took part in the vote at Middleton, Wisconsin-based Raven, on May 23 amid opposition from Activision management. The move followed years of complaints about excessive…

Why Petco Shares Are Gaining Today

Why Petco Shares Are Gaining Today

Petco Health And Wellness Company Inc (NASDAQ:WOOF) reported first-quarter FY22 sales growth of 4.3% year-on-year, to $1.48 billion, beating the consensus of $1.46 billion. Comparable sales growth was 5.1%. The gross profit rose 2% Y/Y to $607.7 million with a margin of 41.2%. Selling, general and administrative expenses increased 2% to $557.7 million.…

Where Cytokinetics Stands With Analysts

Where Cytokinetics Stands With Analysts

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Why Zoom Shares Are Rising Today

Why Zoom Shares Are Rising Today

Zoom Video Communications Inc (NASDAQ: ZM) shares are trading higher Tuesday morning after the company reported better-than-expected financial results and issued guidance above analyst estimates.

FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer

FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer

The FDA has removed the partial clinical hold placed on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial of davoceticept (ALPN-202) in advanced malignancies. Davoceticept is a first-in-class conditional CD28 costimulator and a dual checkpoint inhibitor. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. The trial is evaluating davoceticept…

Fintech Spotlight: FTX Floating Acquisitions Of Webull, Apex And Public.com

Fresh after CEO Sam Bankman-Fried disclosed a stake in Robinhood Markets Inc (NASDAQ: HOOD), FTX reportedly is in talks regarding acquisitions with large firms including Webull, Public.com, and Apex Clearing.

Expect More Musk-Related Fireworks At Twitter Shareholder Meeting This Week: Wedbush Analyst

Expect More Musk-Related Fireworks At Twitter Shareholder Meeting This Week: Wedbush Analyst

Twitter Inc’s (NASDAQ: TWTR) special meeting with shareholders on Wednesday is expected to kick off some more fireworks between Tesla Inc (NASDAQ: TSLA) CEO Elon Musk and the micr

Get all your
news in one place.

100’s of premium titles.
One news app.

TENX: 1Q:22 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Why SpringWorks Shares Are Soaring Today Premarket

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors.

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Get all your
news in one place.

100’s of premium titles.
One news app.

Morning Brief: Top Financial Stories Dominating on Tuesday, May 24

Canadian Solar Misses Q1 Revenue Amid Challenging Operating Environment

Canadian Solar Inc (NASDAQ:CSIQ) reported first-quarter FY22 revenue growth of 15% year-on-year to $1.25 billion, missing the consensus of $1.31 billion. Higher solar shipment volumes and ASP and a significant increase in the battery storage solutions business drove the growth. Solar module shipments of 3.63 GW, up 42% Y/Y, were in line with…

Recap: Petco Health and Wellness Q1 Earnings

Petco Health and Wellness (NASDAQ:WOOF) reported its Q1 earnings results on Tuesday, May 24, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Recap: Ituran Location & Control Q1 Earnings

Ituran Location & Control (NASDAQ:ITRN) reported its Q1 earnings results on Tuesday, May 24, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Recap: Canadian Solar Q1 Earnings

Canadian Solar (NASDAQ:CSIQ) reported its Q1 earnings results on Tuesday, May 24, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

10 Biggest Price Target Changes For Tuesday

Needham reduced WalkMe Ltd. (NASDAQ: WKME) price target from $40 to $20. WalkMe shares dropped 8.1% to close at $12.20 on Monday.

iMedia Brands Clocks 37% Top-Line Growth In Q1; Reiterates FY22 Outlook

iMedia Brands Inc (NASDAQ:IMBI) reported first-quarter FY22 sales growth of 37% year-on-year to $154.5 million, marginally beating the consensus of $154.44 million. Total 12-month rolling active customers grew by 48% Y/Y, driven by the continued strong customer growth from Christopher & Banks and the addition of the 123tv customer file. The gross margin…

1 … 447 448 449 450

People

Mark Zuckerberg

Sam Bankman-Fried

Justin Patterson

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

340,470 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play